share_log

Laidlaw & Co. Initiates Coverage On Bellerophon Therapeutics With Buy Rating, Announces Price Target of $35

Laidlaw & Co. Initiates Coverage On Bellerophon Therapeutics With Buy Rating, Announces Price Target of $35

Laidlaw & Co.以買入評級啓動對Bellerophon Therapeutics的報道,宣佈目標股價爲35美元
Benzinga ·  2023/05/09 10:07

Laidlaw & Co. analyst Yale Jen initiates coverage on Bellerophon Therapeutics (NASDAQ:BLPH) with a Buy rating and announces Price Target of $35.

Laidlaw & Co. 分析師耶魯·詹以買入評級開始對Bellerophon Therapeutics(納斯達克股票代碼:BLPH)進行報道,並宣佈目標股價爲35美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論